Vacc-4x

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2018
012320022018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES The REDUC clinical study Part B investigated Vacc-4x/rhuGM-CSF therapeutic vaccination prior to HIV latency reversal… (More)
Is this relevant?
2016
2016
BACKGROUND Immune priming before reversal of latency might be a component of a functional HIV cure. To assess this concept, we… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2014
2014
BACKGROUND Present combination antiretroviral therapy (cART) alone does not cure HIV infection and requires lifelong drug… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2014
2014
BACKGROUND Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Vacc-4x is being developed by Bionor Immuno AS as a therapeutic vaccine to be used in conjunction with antiretroviral therapies… (More)
Is this relevant?
2009
2009
In this article, we perform a statistical analysis of reoccurrence of opportunistic diseases for HIV-1 infected patients… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
We have previously shown that HIV p24-like peptides (Vacc-4x) via activation of skin dendritic cells induced immune responses in… (More)
Is this relevant?
2004
2004
OBJECTIVE The Vacc-4x immunotherapy candidate is composed of four modified peptides corresponding to conserved domains of the HIV… (More)
Is this relevant?
2002
2002
Highly active antiretroviral therapy (HAART) can effectively suppress HIV-1 replication but, as soon as the drugs are withdrawn… (More)
Is this relevant?